AU2002339169A1 - Solid pharmaceutical composition comprising 4-cyano-trifluoro-3-(4-fluorophenyl sulphonyl)-2-hydroxy-2-methylpropiono- m toluidide, pvp, an anti-oestrogen and/or an aromatase inhibitor - Google Patents
Solid pharmaceutical composition comprising 4-cyano-trifluoro-3-(4-fluorophenyl sulphonyl)-2-hydroxy-2-methylpropiono- m toluidide, pvp, an anti-oestrogen and/or an aromatase inhibitorInfo
- Publication number
- AU2002339169A1 AU2002339169A1 AU2002339169A AU2002339169A AU2002339169A1 AU 2002339169 A1 AU2002339169 A1 AU 2002339169A1 AU 2002339169 A AU2002339169 A AU 2002339169A AU 2002339169 A AU2002339169 A AU 2002339169A AU 2002339169 A1 AU2002339169 A1 AU 2002339169A1
- Authority
- AU
- Australia
- Prior art keywords
- methylpropiono
- toluidide
- oestrogen
- pvp
- trifluoro
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
SE0103838A SE0103838D0 (en) | 2001-11-16 | 2001-11-16 | Pharmaceutical formulation & product |
SE0103838-9 | 2001-11-16 | ||
PCT/GB2002/005158 WO2003043630A1 (en) | 2001-11-16 | 2002-11-14 | Solid pharmaceutical composition comprising 4-cyano-trifluoro-3-(4-fluorophenyl sulphonyl)-2-hydroxy-2-methylpropiono- m toluidide, pvp, an anti-oestrogen and/or an aromatase inhibitor |
Publications (1)
Publication Number | Publication Date |
---|---|
AU2002339169A1 true AU2002339169A1 (en) | 2003-06-10 |
Family
ID=20286022
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU2002339169A Abandoned AU2002339169A1 (en) | 2001-11-16 | 2002-11-14 | Solid pharmaceutical composition comprising 4-cyano-trifluoro-3-(4-fluorophenyl sulphonyl)-2-hydroxy-2-methylpropiono- m toluidide, pvp, an anti-oestrogen and/or an aromatase inhibitor |
Country Status (3)
Country | Link |
---|---|
AU (1) | AU2002339169A1 (en) |
SE (1) | SE0103838D0 (en) |
WO (1) | WO2003043630A1 (en) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20050008691A1 (en) * | 2003-05-14 | 2005-01-13 | Arturo Siles Ortega | Bicalutamide compositions |
NZ580384A (en) | 2003-07-23 | 2011-03-31 | Bayer Pharmaceuticals Corp | 4{4-[3-(4-chloro-3-trifluoromethylphenyl)-ureido]-3-fluorophenoxy}-pyridine-2-carboxylic acid methylamide and metabolites for the treatment and prevention of diseases and conditions |
MY142989A (en) | 2004-03-10 | 2011-02-14 | Bayer Schering Pharma Ag | Stabilised supersaturated solids of lipophilic drugs |
MY191349A (en) * | 2004-08-27 | 2022-06-17 | Bayer Pharmaceuticals Corp | New pharmaceutical compositions for the treatment of hyper-proliferative disorders |
CN101272848B (en) * | 2005-07-28 | 2013-03-13 | Isp投资有限公司 | Method to improve characteristics of spray dried powders and granulated materials, and the products thereby produced |
EP2125938A2 (en) | 2007-01-26 | 2009-12-02 | Isp Investments Inc. | Formulation process method to produce spray dried products |
CN104146974B (en) * | 2014-08-14 | 2016-09-07 | 杭州华东医药集团新药研究院有限公司 | A kind of compositions containing letrozole and preparation method thereof |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE4318371A1 (en) * | 1993-05-28 | 1994-12-01 | Schering Ag | Agent containing a compound with antiandrogenic and a compound with competitive, progesterone-antagonistic effect |
ES2307482T3 (en) * | 1999-02-10 | 2008-12-01 | Pfizer Products Inc. | SOLID PHARMACEUTICAL DISPERSIONS. |
GB9930839D0 (en) * | 1999-12-30 | 2000-02-16 | Pharmacia & Upjohn Spa | Process for treating gynecomastia |
GB0012291D0 (en) * | 2000-05-23 | 2000-07-12 | Astrazeneca Ab | Pharmaceutical combination |
SK10722003A3 (en) * | 2001-02-27 | 2004-02-03 | Astrazeneca Ab | Pharmaceutical formulation comprising bicalutamide in solid dispersion with an enteric polymer and use thereof |
PL365330A1 (en) * | 2001-04-02 | 2004-12-27 | Astrazeneca Ab | Solid pharmaceutical composition comprising 4 -cyano-trifluoro-3-(4-fluorophenylsulphonyl)-2-hydroxy-2-methylpropiono- m toluidide and pvp |
-
2001
- 2001-11-16 SE SE0103838A patent/SE0103838D0/en unknown
-
2002
- 2002-11-14 AU AU2002339169A patent/AU2002339169A1/en not_active Abandoned
- 2002-11-14 WO PCT/GB2002/005158 patent/WO2003043630A1/en not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
SE0103838D0 (en) | 2001-11-16 |
WO2003043630A1 (en) | 2003-05-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2002349001B2 (en) | Pharmaceutical containing 3-(3-dimethylamino-1-ethyl-2-methyl-propyl)phenol and providing delayed release of the active ingredient | |
AU2002349001A1 (en) | Pharmaceutical containing 3-(3-dimethylamino-1-ethyl-2-methyl-propyl)phenol and providing delayed release of the active ingredient | |
AU2002363236A1 (en) | Compounds, pharmaceutical compositions and methods of use therefor | |
HUP0303454A3 (en) | Solid pharmaceutical composition comprising 4-cyano-trifluoro-3(4-fluorophenyl-sulphonyl)-2-hydroxy-2-methylpropiono-m toluidide and pvp | |
MXPA03009410A (en) | Orally deliverable pharmaceutical composition comprising an active compound having an aminosulfonyl group (cox-2 inhibitor), a polyethylene glycol and a free-radical scavenging antioxidant. | |
EP1587474A3 (en) | Fluoroalkoxy-substituted 1, 3-dihydro-isoindolyl compounds and their pharmaceutical uses | |
HUP0303644A3 (en) | Pyridazinone-derivatives aldose reductase inhibitors, their use and pharmaceutical compositions containing them | |
AU2001291781A1 (en) | Active ingredient combinations comprising insecticidal and acaricidal properties | |
AU2002302147A1 (en) | Pharmaceutical composition | |
WO2002089788A3 (en) | Pharmaceutical compositions comprising a hmg-coa reductase inhibitor | |
HUP0402028A3 (en) | Unsaturated 1-amino-alkylcyclohexane derivatives, pharmaceutical compositions containing them and use thereof | |
AU2002339169A1 (en) | Solid pharmaceutical composition comprising 4-cyano-trifluoro-3-(4-fluorophenyl sulphonyl)-2-hydroxy-2-methylpropiono- m toluidide, pvp, an anti-oestrogen and/or an aromatase inhibitor | |
AU2001265305A1 (en) | Compositions containing hexitol and an antiproliferative agent | |
AU2002330233A1 (en) | Pharmaceutical composition having prophylactic effects on lamivudine-related disease relapse and drug resistance and methods of using the same | |
AU2003236076A1 (en) | Hydrophilic polymers-flavonoids conjugates and pharmaceutical compositions comprising them | |
AU2002341555A1 (en) | Levothyroxine pharmaceutical compositions, methods of making and methods of administration | |
AUPR277401A0 (en) | Physiologically active bracing | |
AU2003283508A1 (en) | .pharmaceutical composition comprising htless thansbgreater than4less than/sbgreater thandless thanspgreater than100less than/spgreater thana receptors, and therapeutic uses thereof | |
AU2002346860A1 (en) | Pharmaceutical containing 3-(3-dimethylamino-1-ethyl-2-methyl-propyl)phenol and providing delayed release of the active ingredient | |
AU2001243979A1 (en) | Papaine containing pharmaceutical formulation resp. its use | |
AU2002245959A1 (en) | An antioxidant composition and a cosmetic or pharmaceutical composition | |
AU2002345558A1 (en) | Surface-doped plaster containing an active ingredient | |
AU2002242909A1 (en) | Pharmaceutical composition comprising ibuprofen and prochlorperazine | |
AU2002244962A1 (en) | Pyrazolecarboxamide derivative, intermediate therefor, and pest control agent containing the same as active ingredient | |
AU2002230128B2 (en) | Novel physiologically active substances |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MK6 | Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase |